E. Ohman J or Asset Management AB Has $721,000 Holdings in Scholar Rock Holding Corporation $SRRK

E. Ohman J or Asset Management AB decreased its holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 76.6% during the 4th quarter, Holdings Channel.com reports. The fund owned 16,374 shares of the company’s stock after selling 53,513 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Scholar Rock were worth $721,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ramirez Asset Management Inc. bought a new stake in Scholar Rock during the 3rd quarter worth approximately $37,000. Penserra Capital Management LLC bought a new position in shares of Scholar Rock in the third quarter valued at approximately $56,000. Strs Ohio purchased a new position in shares of Scholar Rock during the first quarter valued at approximately $77,000. Bessemer Group Inc. boosted its position in shares of Scholar Rock by 970.0% during the third quarter. Bessemer Group Inc. now owns 2,322 shares of the company’s stock valued at $86,000 after buying an additional 2,105 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new stake in Scholar Rock during the second quarter worth $94,000. 91.08% of the stock is owned by institutional investors.

Scholar Rock Stock Performance

Shares of SRRK opened at $45.43 on Thursday. The stock has a 50 day moving average of $45.15 and a 200 day moving average of $40.19. The company has a market capitalization of $5.22 billion, a price-to-earnings ratio of -13.24 and a beta of 0.70. Scholar Rock Holding Corporation has a 12 month low of $22.71 and a 12 month high of $49.82. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.41.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.10. During the same period in the previous year, the firm posted ($0.64) earnings per share. As a group, sell-side analysts forecast that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Mo Qatanani sold 8,484 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $47.07, for a total value of $399,341.88. Following the transaction, the insider directly owned 98,445 shares of the company’s stock, valued at approximately $4,633,806.15. The trade was a 7.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jing L. Marantz sold 4,157 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $193,425.21. Following the transaction, the insider owned 126,012 shares of the company’s stock, valued at approximately $5,863,338.36. The trade was a 3.19% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 207,464 shares of company stock valued at $9,157,423. 13.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on SRRK shares. HC Wainwright reissued a “buy” rating and issued a $58.00 price target on shares of Scholar Rock in a research report on Tuesday, March 3rd. Truist Financial lifted their price objective on shares of Scholar Rock from $44.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Piper Sandler upped their target price on shares of Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 4th. UBS Group began coverage on shares of Scholar Rock in a report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 target price for the company. Finally, JPMorgan Chase & Co. raised their price target on shares of Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, March 16th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Scholar Rock presently has a consensus rating of “Buy” and a consensus target price of $54.36.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).